Panel on public service drugs and new uses for old drugs

Atkinson, Arthur J.; Finkel, Marion J.; Burns, J. J.; Hitchings, George H.; Kemp, Bernard A.; Dennis, Susana R. K. de

doi:10.1002/cpt1975185part2659

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug repurposing, where new indications are identified for existing drugs, has gained attention in recent years as a practical means to bypass the slow and costly process of introducing new drugs [22-26]. The rationale for repurposing need not be based on implicating the known drug target or a related activity in a new disease.…”

Section: Discussionmentioning

confidence: 99%

Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers

et al. 2016

View full text Add to dashboard Cite

Radiation therapy remains a significant therapeutic modality in the treatment of cancer. An attractive strategy would be to enhance the benefits of ionizing radiation (IR) with radiosensitizers. A high-content drug repurposing screen of approved and investigational agents, natural products and other small molecules has identified multiple candidates that blocked repair of IR damage in vitro. Here, we validated a subset of these hits in vitro and then examined effects on tumor growth after IR in a murine tumor model. Based on robust radiosensitization in vivo and other favorable properties of cephalexin, we conducted additional studies with other beta-lactam antibiotics. When combined with IR, each cephalosporin tested increased DNA damage and slowed tumor growth without affecting normal tissue toxicity. Our data implicate reactive oxygen species in the mechanism by which cephalosporins augment the effects of IR. This work provides a rationale for using commonly prescribed betalactam antibiotics as non-toxic radiosensitizers to enhance the therapeutic ratio of radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Drug repurposing (also known as drug repositioning or drug reprofiling) is the process of redeveloping a compound for use in a different disease [39] and is now becoming an increasingly important strategy for researchers in industry and academia [40]. Although this strategy is far from new, repurposing success stories and companies leveraging repurposing strategies are increasing in number [41,42]. They are based on the following core scientific principles: (i) single drugs often interact with multiple targets or pathways, and (ii) various drugs may act on the same target or pathway [43][44][45].…”

Section: Drug Repurposing: a Cheaper And Faster Optionmentioning

confidence: 99%

Drug Repurposing for Rare Diseases

Roessler

Knoers

Haelst

et al. 2021

Trends in Pharmacological Sciences

145

View full text Add to dashboard Cite

“…Line extension is an application for a pharmaceutical product that only differs in pharmaceutical form and/or strength from one or more other pharmaceutical products for which the applicant either holds a marketing authorization, or has submitted a marketing authorization application Escitalopram (an enantiomer of citaloparam) an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class is a line extension of citaloparam Therapeutic switching Practice of replacing a patient's prescription drugs with chemically different drugs that are expected to have the same clinical effect Switching from one antidepressant to another based on clinical evaluation or other patient specific needs classification system [1,2,[7][8][9][15][16][17][18][19][20][21][22][23][24][25][26][27][28]. The concept of using approved or regulated drugs for new indications can be traced back to the 1950s [29,30]. The use of reticulose (lipoprotein nucleic acid complex) as a drug for postradiation effects is among the earliest examples of drug repositioning.…”

Section: Line Extensionmentioning

confidence: 99%

Computational and Experimental Advances in Drug Repositioning for Accelerated Therapeutic Stratification

Shameer¹,

Readhead²,

Dudley

2015

CTMC

View full text Add to dashboard Cite

Drug repositioning is an important component of therapeutic stratification in the precision medicine paradigm. Molecular profiling and more sophisticated analysis of longitudinal clinical data are refining definitions of human diseases, creating needs and opportunities to re-target or reposition approved drugs for alternative indications. Drug repositioning studies have demonstrated success in complex diseases requiring improved therapeutic interventions as well as orphan diseases without any known treatments. An increasing collection of available computational and experimental methods that leverage molecular and clinical data enable diverse drug repositioning strategies. Integration of translational bioinformatics resources, statistical methods, chemoinformatics tools and experimental techniques (including medicinal chemistry techniques) can enable the rapid application of drug repositioning on an increasingly broad scale. Efficient tools are now available for systematic drug-repositioning methods using large repositories of compounds with biological activities. Medicinal chemists along with other translational researchers can play a key role in various aspects of drug repositioning. In this review article, we briefly summarize the history of drug repositioning, explain concepts behind drug repositioning methods, discuss recent computational and experimental advances and highlight available open access resources for effective drug repositioning investigations. We also discuss recent approaches in utilizing electronic health record for outcome assessment of drug repositioning and future avenues of drug repositioning in the light of targeting disease comorbidities, underserved patient communities, individualized medicine and socioeconomic impact.

show abstract

Panel on public service drugs and new uses for old drugs

Cited by 3 publications

References 0 publications

Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers

Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers

Drug Repurposing for Rare Diseases

Computational and Experimental Advances in Drug Repositioning for Accelerated Therapeutic Stratification

Contact Info

Product

Resources

About